Zu den Inhalten springen
International Medical Services & Business Development
Official Site of the Medical Center – University of Freiburg


Nuclear Medicine

  • Clinical and scientific focus on Oncology, Neurology and Endocrinology
  • In-house development and production of innovative radiopharmaceuticals
  • Innovative radionuclide therapies (e.g., in neuroendocrine,  liver and prostate tumors)



The Department of Nuclear Medicine uses radiopharmaceuticals for diagnostics and treatment of various diseases with particular emphasis on endocrine, cancerous and neurological diseases. While diagnostic procedures can be performed on an out-patient basis, most treatments with radioactive substances are done on an in-patient basis to achieve optimal results and to comply with German radiation protection law.

Our therapeutic facility is named after George von Hevesy, a Hungarian pioneer of Nuclear Medicine and Noble Prize winner, who worked as Professor for Physical Chemistry at the University of Freiburg.

The Department of Nuclear Medicine of the Medical Center - University of Freiburg is licensed as a training center for nuclear medicine by the European Board of Nuclear Medicine.


Diagnostic & Treatment Services

  • Specialized clinic for benign and malignant thyroid diseases, offering the full spectrum of modern diagnostic and therapeutic options
  • Scintigraphy, SPECT and SPECT/CT for diseases of the thyroid, skeleton, myocardium, lungs, kidneys and brain. Visualization of lymphatic drainage for sentinel lymph node resection. Support of radioguided surgery
  • Innovative therapies, e.g., Peptide-Receptor Radionuclide Therapy (PRRT) for neuroendocrine tumors, radioligand therapy targeting the Prostate-Specific Membrane Antigen (PSMA) in prostate cancer, Selective Internal Radiation Therapy (SIRT) of liver tumors
  • state-of-the-art PET/CT technology (e.g., full-digital and time-of-flight PET imaging) with numerous molecular imaging probes for:
    • Oncology: Detection, staging and treatment monitoring of cancer, in particular lung cancer, lymphoma, gastrointestinal malignancies, prostate cancer, melanoma, neuroendocrine and brain tumors. Molecular imaging targets include glucose metabolism, amino acid transport, PSMA, hormone synthesis and receptors, and hypoxia. PET-based radiation treatment planning, especially for stereotactic and intensity modulated radiotherapy.
    • Neurology: State-of-the-art diagnostics, differential diagnostics and follow-up of neurodegenerative disorders, most notably mild cognitive impairment (MCI), dementia (e.g., Alzheimer’s disease) and movement disorders (e.g., Parkinson’s disease). Localization of epileptogenic foci in patients with seizures. Molecular imaging targets include glucose metabolism, perfusion, a variety of neurotransmitter receptors and transporters (e.g., dopaminergic) and neuropathology imaging (amyloid-beta and tau).
    • Cardiology: Diagnosis, follow-up and prognostication of coronary heart disease. Detection of viable myocardium prior to revascularization. Diagnosis of acute and chronic lung embolism; presurgical assessment of lung function.
    Read more about PET/CT
  • Molecular Therapy
    • Radioiodine therapy of hyperthyroidism and goiter
    • Radioiodine therapy and targeted therapies in thyroid cancer
    • PRRT of neuroendocrine tumors (e.g., with [177Lu]DOTA-TATE and other ligands)
    • PSMA-targeting radioligand therapy in prostate cancer
    • Treatment of primary and secondary liver tumors with SIRT
    • Radionuclide therapy of symptomatic bone metastases (e.g., 223Radium and other ligands)
  • Second Opinion Service


medical doctors14
basic scientists12

  • more than 12,000 diagnostic examinations (including >3000 PET/CT scans) and about 700 radionuclide treatments per year

Our team (board certified)

  • Prof. Dr. Dr. Philipp T. Meyer

    Medical Director

  • Prof. Dr. Juri Ruf

    Vice Medical Dirctor

  • PD Dr. Dr. Christian Götz